Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.
Michot, J-M
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 07 2020 - 961-964 p. digital
Publication Type: Case Reports; Letter
1569-8041
10.1016/j.annonc.2020.03.300 doi
Adult
Antibodies, Monoclonal, Humanized--therapeutic use
Autoantibodies--therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections--complications
Humans
Male
Pandemics
Pneumonia, Viral--complications
Receptors, Interleukin-6--antagonists & inhibitors
Respiratory Insufficiency--diagnostic imaging
SARS-CoV-2
Treatment Outcome
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 07 2020 - 961-964 p. digital
Publication Type: Case Reports; Letter
1569-8041
10.1016/j.annonc.2020.03.300 doi
Adult
Antibodies, Monoclonal, Humanized--therapeutic use
Autoantibodies--therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections--complications
Humans
Male
Pandemics
Pneumonia, Viral--complications
Receptors, Interleukin-6--antagonists & inhibitors
Respiratory Insufficiency--diagnostic imaging
SARS-CoV-2
Treatment Outcome